Back to all webinars
BeiGeneius Hematology Summit – Relapsed/refractory CLL and indolent lymphomas
A multidisciplinary panel review the latest developments in R/R CLL and indolent lymphomas and share expert overviews of clinical trial interpretation and best practice in patient communication.
Speakers
Recent advances in R/R CLL
No entries
Clinical scenarios in R/R CLL
No entries
Recent advances in R/R indolent lymphomas
No entries
Audience-directed discussion: Future challenges in indolent lymphomas
No entries
Debate: Bispecific antibodies are a better therapeutic option than CAR-T therapies for early relapsing FL
No entries
How to interpret a trial: Design and statistics
No entries
Improving communication between hematologists and patients: Talking about risk, uncertainty, and clinical trials
No entries